Furthermore, YHJD can inhibit liver metastasis of colorectal cancer (CRC) in vivo, and its therapeutic effect is closely related to the regulation of multiple targets and effector processes, especially the PI3K-AKT signaling pathway and the immune response dominated by natural killer (NK) cells 25. This evidence concerns the gene AKT1 and colorectal cancer.